Life Technologies Develops Potent Drug Delivery Technology for Therapeutics Market

CARLSBAD, Calif., July 14, 2011 /PRNewswire/ -- Life Technologies Corporation today announced that it has developed new drug delivery technology specially designed for therapeutic applications that is 100-fold more potent than previous formulations. The technology is available for licensing as part of a new out-licensing program.

Scientists at Life Technologies have developed the novel proprietary siRNA delivery reagents by using new lipid molecules and formulation design to drastically improve potency and minimize toxicity in vivo. A single dose of 12.5ug siRNA per kilogram can achieve 50 percent knock down of a target gene, said Keith Farnsworth, product management leader at Life Technologies.

"Historically, delivery of siRNA has been problematic due to the high risk of toxicity and hampered efficiency," he said. "Life Technologies' new formulations provide the pharmaceutical and biotech industries a viable platform to help develop siRNA drugs that overcome these challenges."

The availability of the new formulations follows Life Technologies' 2010 launch of Invivofectamine 2.0®, a lipid-based siRNA delivery technology for the research market that can knock down up to four genes in vivo in lab models for extended periods with a single application. The novel formulations available through the out-licensing program use different molecules that make it ideal for therapeutic applications.

For more information, contact Maya Tanaka, Sr. Manager, Business Development and Licensing, (760) 268-7982; [email protected]

About Life Technologies (www.lifetechnologies.com)

Life Technologies Corporation is a global biotechnology company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics. The company manufactures both molecular diagnostic and research use only products. Life Technologies' industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, GIBCO, Ambion, Molecular Probes and TaqMan^® products. Life Technologies had sales of $3.6 billion in 2010, has a workforce of approximately 11,000 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 3,900 patents and exclusive licenses. For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com.

Life Technologies' Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

(Logo:  http://photos.prnewswire.com/prnh/20110216/MM49339LOGO)

Life Technologies Contact
Mauricio Minotta
760-929-2456
[email protected]

SOURCE Life Technologies Corporation

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED